I emailed Fred Sommer a few days ago asking for an update
I emailed Fred Sommer a few days ago asking for an update on the JV. His response:
"until a deal is finalized we are staying the course"
All that really matters at this point is what kind of deal they can get for ESS and how much cash upfront they can get. I posted this earlier and now it's even more true. The scary part of the RS is the AS stays the same so they could continue to issue large blocks of more stock to raise more money after the RS, making the common stock holders own a smaller and smaller portion of the company.
What is interesting about this proxy is that they give a range from 2:1- 300:1. and they say they may not even do a reverse split at all.
Has anyone on this board ever seen a proxy where they state a range and they also state they may not even do a reverse split? Every time I've seen when a RS is proposed, they at least state whether nor not they are actually doing it. The vote will either be for a specific ratio, like 1:150 or the vote will give the BOD the right to determine what the ratio will be, but either way the vote is for or against a RS actually happening. Here the vote is giving the BOD the right to do a RS but they may not do one at all. In other words, the board doesn't even know yet whether or not they are going to want to do a RS. Why not? Why not just ask for an approval and do the RS right after the vote? I also have never seen a range stated in a proxy- maybe someone else has. I'm sure if it has been done, it' s never done with such a huge range as this.
Think about that- the company says it may be necessary to do a 1:300 RS, but may not do a RS at all- are you kidding me?- it doesn't make any sense.
Which is why I believe they are doing this as a back-up plan if they are unable to finish a deal for ESS in time before they need more money. But hopefully if they get enough cash they either cancel the RS or maybe do a small one next year. Fred said a couple months ago the RS was no longer being considered. Remember they also said they were doing a RS in June and never did. I am guessing the negotiations have either stalled or just taking longer than they thought. This may also be away of negotiating with the partner at the table to show that they are willing to walk and continue to dilute the SH instead of taking the deal offered. Hopefully we'll get some news soon.
9
Amarantus Bioscience Holdings (AMBS) Stock Research Links
Scroll down for more posts ▼
Top 10 Most Recent News Articles
Reclined car seats are becoming a real engineering headache, not some showroom gimmick, and Autoliv has put a marker down with Omni Safety™. The company received 2026 Automotive News PACE Pilot recognition for the system, which tackles occupant protection when people are sitting farther back than conventional vehicle safety designs assumed. That matters because...
Continue Reading
Orbit got a little less theoretical when Sophia Space put its operating system across multiple Kepler Communications satellites. That is not a finished orbital data center, despite the inevitable big-language parade around this sort of announcement. It is a software deployment, a real one, aboard Kepler's Tranche 1 optical data relay constellation. In an industry stuffed...
Continue Reading
One star swallowed another’s orbit, and astronomy finally caught the evidence. That is the plain-English punch of the observation called AT 2025abao in the Andromeda Galaxy, and it is a meaningful one for Jason Nordhaus and his colleagues at Rochester Institute of Technology. On Nov. 18, research published in Nature validated a scenario Nordhaus’s team had predicted...
Continue Reading
A 19.8% shareholder heading for the exit can rattle a shipping stock before breakfast, and TORM has answered the noise with a flat refusal to pretend Hafnia's merger approach was good enough. The message from Hellerup on November 18 is unusually blunt: Hafnia made several conditional, all-share proposals, TORM saw no effective premium for control, and the board rejected...
Continue Reading
A slim E-Ink notebook is getting shoved into the Black Friday brawl, and iFLYTEK is betting that less screen glare and more follow-through can still command a serious price. The company has put discounts of up to 25% on its AINOTE lineup, a sensible move in a gadget season where buyers have no shortage of tablets, voice apps, and half-used productivity subscriptions...
Continue Reading
India's power market is not a tidy spreadsheet, thankfully. It is a vast, fast-growing grid where data centres, factories and climate exposure are all colliding with a generation mix still dominated by coal. That is why LevelTen Energy's move into Asia-Pacific deserves more than the usual clean-tech applause line. Beginning with a 500 MW clean-energy request for proposals...
Continue Reading
Pain-care consolidation has a peculiar way of looking tidy in a release and messy in the real world. Resolve Pain Solutions announced on November 18, 2026, that it has acquired Cahaba Pain and Spine Care, an established provider serving greater Birmingham, Alabama. On its face, this is a straightforward expansion move: buy a respected local practice, retain its physician...
Continue Reading
A postcard-perfect balcony can hide a remarkably expensive rulebook. That is the unglamorous message in Angie Outlaw’s discussion of vacation-property buying in Panama City Beach: the view may sell the unit, but zoning, association documents, insurance and lender terms determine whether the purchase behaves anything like the income-producing asset a buyer pictured. I...
Continue Reading
California’s rainy-day umbrella is getting another hard look, and it should. State Controller Malia M. Cohen is pointing to the Legislative Analyst’s Office fiscal outlook as a reminder that budget discipline and stronger reserves are not ornamental good-government phrases. They are the difference between absorbing a revenue wobble and reaching for ugly fixes after...
Continue Reading
A school group that once opened 35 kindergartens in a year is admitting the old playbook has run its course. That is the real message behind Oriental Cambridge Education Group's 40th-anniversary talk, not the balloons and ceremonial language. OCEG operates more than 170 institutions across 39 Chinese cities, and its chairman, Yu Yue, says the next chapter will be judged...
Continue Reading
Top 5 Most Recently Viewed Articles
Radius Insights Launches Radius Tech A focused expansion of Radius' technology expertise aims to help tech brands make smarter, faster growth decisions. Radius Insights recently unveiled the launch of Radius Tech, a dedicated technology division within Radius designed to deliver precise market research and customer insights specifically tailored for technology companies....
Continue Reading
Important Information for WM Technology Shareholders The Gross Law Firm is reaching out to shareholders of WM Technology, Inc. (NASDAQ: MAPS). This notice serves as a crucial reminder regarding the upcoming deadline for appointing a lead plaintiff in the class action lawsuit involving the company. Who Should Contact the Gross Law Firm? If you have purchased shares of MAPS...
Continue Reading
Gaxos.ai's Involvement at Unite 2024 Conference Gaxos.ai Inc. is preparing for a major presence at the Unite 2024 Conference, a vibrant event dedicated to showcasing the latest innovations in gaming and technology. This conference is well-known for bringing together game developers, artists, and tech enthusiasts. Running from September 18 to September 20, Gaxos is eager...
Continue Reading
XNRGY Climate Systems Strengthens Financial Foundation XNRGY Climate Systems, recognized as a key player in sustainable technologies, recently revealed that it has effectively finalized its financing round. This includes a significant investment partnership with Capital Bridge Group and Prologis Ventures. With this move, XNRGY aims to push forward its mission of advancing...
Continue Reading
BioLife Solutions Completes Strategic Sale of SAVSU BioLife Solutions, Inc. (Nasdaq: BLFS), a prominent provider of cell processing tools for the cell and gene therapy market, has recently announced a significant event in its operational strategy. The company has sold its wholly owned cold chain logistics subsidiary, SAVSU Cleo Technologies, LLC., previously known as...
Continue Reading